anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention provides a microfluidic mixing device and a one-step preparation method of a targeted liposome. The microfluidic mixing device comprises a microfluidic chip, a sealing soft membrane and a clamping and fixing assembly. The micro-fluidic chip is provided with a buffer solution inlet, a lipid organic solution inlet, a fluid focusing mixing unit, a snake-shaped/herringbone mixing unit, a targeting ligand solution inlet, a Tesla mixing unit and an outlet. The solution mixing unit is arranged on one side of the microfluidic chip, sealed through a sealing soft film and clamped through a clamping and fixing assembly. The clamping and fixing component consists of a bolt and a nut, a perforated thin plate and a matching thin plate. The microfluidic mixing device can realize one-step synthesis of the targeted liposome in the same device, greatly shortens the process time and reduces the operation steps. In addition, the microfluidic mixing device has the advantage of being detachable, can conveniently clean and dredge the solution mixing unit after the sealing soft membrane is removed, and has excellent reusability.
The invention discloses an antitumor drug with double active components, and an application thereof. The antitumor drug comprises an independent first active component and an independent second active component. The independent first active component comprises at least two of A, B and C. The A comprises Dipyridamole and pharmaceutically acceptable derivatives of Dipyridamole or pharmaceutically acceptable analogues of Dipyridamole or pharmaceutically acceptable salts of Dipyridamole. The B comprises Ubenimex bestatin and pharmaceutically acceptable derivatives of Ubenimex bestatin or pharmaceutically acceptable analogues of Ubenimex bestatin or pharmaceutically acceptable salts of Ubenimex bestatin. The C comprises Dexamethasone and pharmaceutically acceptable derivatives of Dexamethasone or pharmaceutically acceptable analogues of Dexamethasone. The independent second active component comprises Taxol, ADM, DDP, MMC, 5-FM, Gemcitabine or a tyrosine kinase inhibitor. The antitumor drug provided by the invention can effect on multiple targets and multiple paths, and thus antineoplastic effects of the antitumor drug are clear and obvious.
PURPOSE: The progression of deep endometriosis (DE) in women of reproductive age is highly variable. This study aimed to analyze the sonomorphological changes of rectal endometriosis over long periods of time and the influence of hormonal treatment.
METHODS: This retrospective study included premenopausal women with rectal DE treated conservatively between 2002 and 2021. The lesion length and thickness of the nodule were evaluated at regular intervals over time. We created statistical models with mixed effects to identify potential factors influencing lesion progression and regression.
RESULTS: 38 patients were monitored over a mean period of 7.2 (± 4.2) years with a mean of 3.1 (± 2.1) check-ups within the observation period. We detected a significant increase in lesion length until the end of the fourth decade of life. In addition, we found a substantial decrease in the length and thickness of the nodule depending on the length of hormonal treatment.
CONCLUSION: In conservatively managed patients with rectal endometriosis, without hormonal therapy, lesion size can exhibit a moderate increase up to the end of the fourth decade of life, after which it appears to stabilize. This increase does not follow a linear pattern. Hormonal therapy is crucial in impeding further progression, resulting in either a cessation or a regression of lesion growth.
Vortioxetine 10 mg, tablets, orally, once daily followed by a dose adjustment to a maximum of 20 mg, tablets, orally, once daily up to 12 weeks. The dose may be decreased by 5 mg based on participant's response and tolerability as judged by the investigator.
After local cleaning of the skin area, the transducer will be placed on the iliac crest in the transverse plane with a low-frequency convex probe, and the skin, subcutaneous tissue, external oblique muscle will be placed with a 20 G, 100 mm needle. After visualization of the internal oblique muscle and transversus abdominis muscles and finally the deep fascia of the transversus abdominis, local anesthetic will be given unilaterally between the last part of the transversus abdominis muscle and the transversalis fascia with the out-off plan technique.
The implantation of a bioprosthetic valve is the established surgical technique when replacing the aortic valve to treat various aortic valve diseases. Many different bioprosthetic valves are available. The design and implantation technique in each system would result in different interaction with the left ventricular outflow tract (LVOT) and the aortic root, leading to different flow profiles that may induce platelet aggregation and affect the long-term performance of the bioprosthesis and its durability. Additionally, complications such as valve thrombosis may occur. However, it is not currently clear which bioprostheses/patients are more prone to thrombosis or degradation of the valve. This study aims to develop fluid-structure interaction (FSI) models, which can model blood flow and wall/valve mechanics, using realistic patient-specific geometries and flow conditions which correlate with the true performance of the valve in the imaged patients, and to assess and compare such performances to understand the benefits and challenges with various bioprosthetic valves.

FSI models combine computational fluid mechanics (CFD) with structural wall mechanics modelling. This is an alternative approach that allows detailed assessment of flow patterns and estimation of wall shear stress and pressure within blood vessels, and therefore has been applied increasingly to gain better insights into the hemodynamics in cardiovascular diseases
The present invention relates to medicine for treating sympathetic nerve disorder with Chinese herbal medicine as raw material, and a preparation method of the medicine. The medicine is composed of the following proportions by weight of components: 5 to 15 parts of safflower, 5 to 15 parts of peach kernels, 3 to 10 parts of arisaema, 10 to 3 parts of albizzia bark, 15 to 25 parts of polygala, 2 to 8 parts of keel, 3 to 10 parts of ligustrum lucidum, 2 to 6 parts of oysters and 10 to 15 parts of wolfberry fruit. The medicine theory of the present invention is based on that Chinese herbal medicine has the functions of tonifying kidneys and yin, tonifying qi deficiency, changing blood quantity, cleaning and discharging turbid articles, and collecting body postures; natural edible plant medicine isogenous with a medicine diet has the efficacy of increasing bioactivity, promoting the reduction of blood fat, improving microcirculation, enhancing internal blood circulation, etc. The medicine has good functions for eliminating and reducing the symptoms of subhealth patients of sympathetic nerve disorder by clinical observation. After the medicine is used, original symptoms are obviously changed; the symptoms of original moderate patients are reduced and removed; severe diseases also disappear. Moreover, the present invention enhances constitutions and enhances immunological functions.
Tobramycin sulfate, a water-soluble antibiotic of the aminoglycoside group, is derived from the actinomycete Streptomyces tenebrarius. Tobramycin Injection, USP is a clear and colorless sterile aqueous solution for parenteral administration. 

Each mL contains tobramycin sulfate equivalent to 40 mg tobramycin; sodium metabisulfite added as an antioxidant, 3.2 mg; and edetate disodium added as a stabilizer, 0.1 mg. Contains sulfuric acid and may contain sodium hydroxide for pH adjustment (3.0 to 6.5). 

Tobramycin sulfate is, O-3-amino-3-deoxy-α-D-glucopyranosyl-(1→4) 

-O-[2,6-diamino-2,3,6-trideoxy-α-D-ribo-hexopyranosyl-(1→6)]-2-deoxy-L-streptamine (2:5)(salt) and has the chemical formula (C18H37N5O9)2 • 5H2SO4. The molecular weight is 1,425.42. The structural formula for tobramycin is as follows: 

A pharmacy bulk package is a container of a sterile preparation for parenteral use that contains many single doses. The contents are intended for use in a pharmacy admixture service and are restricted to the preparation of admixtures for intravenous infusion or to the filling of empty sterile syringes for intravenous injection for patients with individualized dosing requirements. FURTHER DILUTION IS REQUIRED BEFORE USE (see DOSAGE AND ADMINISTRATION, Directions for proper use of Pharmacy Bulk Package).
FIELD: veterinary pharmacology, veterinary science. SUBSTANCE: preparation has dioxydin and streptocid as active agents at amounts 0.68-0.74% and 14.21-14.35% of volume and gelatin-glycerol base - the rest. Preparation is administrated to cows by intravaginal and intrauterine routes at amount 2-5 rods by a single dosing, every other 24 h up to cervix closing. For prophylaxis preparation is administrated as a single dose. Preparation does not show by-side effects. Preparation is suitable for 1 year. EFFECT: enhanced effectiveness of preparation.
The present invention relates to compositions comprising reversibly modified oligonucleotides and uses thereof. Disclosed herein are glutathione-sensitive oligonucleotides and methods of use thereof. Any oligonucleotide of interest can be modified with a glutathione-sensitive moiety, including oligonucleotides for in vivo delivery, such as nucleic acid inhibitor molecules. Typically, the glutathione sensitive moiety is used to reversibly modify the 2' -carbon of the sugar moiety in one or more nucleotides in the oligonucleotide, although other carbon positions may also be modified with the glutathione sensitive moiety. Glutathione-sensitive nucleotides and nucleoside monomers, including glutathione-sensitive nucleoside phosphoramidites, are also disclosed, which are useful, for example, in standard oligonucleotide synthesis methods. In addition, glutathione sensitive nucleotides and nucleoside monomers without phosphoramidites can be used therapeutically, for example, as antiviral agents.
CASE SERIES SUMMARY: This case series describes the use of orally administered dexmedetomidine at a dose of 20 µg/kg to induce emesis in six cats. Emesis was successfully induced in 5/6 cats, with each of the cats vomiting once. The reasons for inducing vomiting included known or suspected ingestion of lilies, onions, acetaminophen (paracetamol) or acetylsalicylic acid. Four of the five cats in which emesis induction was successful did not develop any clinical signs of toxicity associated with the toxin ingested; the fifth cat developed clinicopathological changes consistent with acetaminophen toxicity. All six cats exhibited moderate to profound sedation, as expected, but no other adverse effects were documented.
RELEVANCE AND NOVEL INFORMATION: Induction of emesis in cats is notoriously difficult. This case series describes a novel route of administration of dexmedetomidine, a commonly available medication, with a high success rate observed for inducing emesis in this group of cats.
Colitis has a multifactorial pathogenesis with a strong cross-talk among microbiota, hypoxia, and tissue metabolism. Here, we aimed to characterize the molecular signature of the disease in symptomatic and presymptomatic stages of the inflammatory process at the tissue and fecal level. The study is based on two different murine models for colitis, and HR-MAS NMR on "intact" colon tissues and LC-MS/MS on colon tissue extracts were used to derive untargeted metabolomics and proteomics information, respectively. Solution NMR was used to derive metabolomic profiles of the fecal extracts. By combining metabolomic and proteomic analyses of the tissues, we found increased anaerobic glycolysis, accompanied by an altered citric acid cycle and oxidative phosphorylation in inflamed colons; these changes associate with inflammation-induced hypoxia taking place in colon tissues. Different colitis states were also characterized by significantly different metabolomic profiles of fecal extracts, attributable to both the dysbiosis characteristic of colitis as well as the dysregulated tissue metabolism. Strong and distinctive tissue and fecal metabolomic signatures can be detected before the onset of symptoms. Therefore, untargeted metabolomics of tissues and fecal extracts provides a comprehensive picture of the changes accompanying the disease onset already at preclinical stages, highlighting the diagnostic potential of global metabolomics for inflammatory diseases.
The invention belongs to the technical field of microorganisms. The invention discloses a high-adhesion lactobacillus helveticus with an immunity enhancing function, which is named as WHH2580 and is preserved in the China general microbiological culture collection center in 2019, 10 and 23 months, wherein the microorganism preservation numbers are as follows: CGMCC No. 18730. The microorganism is classified and named Lactobacillus helveticus. The invention also discloses application of the lactobacillus helveticus with the high adhesion performance and the function of enhancing the immunity. The viable bacteria form and the inactivated form of the strain have excellent adhesion performance, and the immunity of the organism is improved by improving the organ index, the non-specific immunity and the specific immune reaction of the organism; the lactobacillus of the invention has immunoregulation function, and if a corresponding composition is taken, the reduction of the immune function can be improved by activating the immune function.
Collagen is an important component, building myocytes and extracellular matrix of skeletal muscles. The novel treatment option for trigger point therapy and muscle regeneration in TMD patients are intramuscular collagen injections. The aim of the study was to evaluate the efficacy of intramuscular injections of Collagen MD Muscle(Guna) 2 ml, 2 ml of Lidocainum 2% without vasoconstrictor and 2 ml of Saline (0,9 % NaCl). 43 patients were enrolled to the study (17 male and 26 female, 40 +/- 3,8 years old). The masseter muscle activity was measured with sEMG Neurobit Optima 4 (Neurobit System). Visual Analogue Scale was used to determine pain intensity changes between follow-up visits in each group. Trigger points were localized with palpation of masseter muscle. Electromyographic activity of masseter muscle was measured before injections on each visit: 0, 7,14 days. In our analysis sEMG masseter muscle activity was significantly decreased: in collagen group 59,2%, in lidocainum group 39,3% and in saline group14%. Pain intensity reduction in VAS scale was 53,75% in collagen group, in lidocainum group 25% and in saline group 20,1%.
BACKGROUND: Atrial fibrillation (AF) is a common arrhythmia characterized by uncoordinated atrial electrical activity. Lone AF occurs in the absence of traditional risk factors and is frequently observed in male endurance athletes, who face a 2- to 5-fold higher risk of AF compared with healthy, moderately active males. Our understanding of how endurance exercise contributes to the pathophysiology of lone AF remains limited. This study aimed to characterize the circulating protein fluctuations during high-intensity exercise as well as explore potential biomarkers of exercise-associated AF.
METHODS AND RESULTS: A prospective cohort of 12 male endurance cyclists between the ages of 40 and 65 years, 6 of whom had a history of exercise-associated AF, were recruited to participate using a convenience sampling method. The circulating proteome was subsequently analyzed using multiplex immunoassays and aptamer-based proteomics before, during, and after an acute high-intensity endurance exercise bout to assess temporality and identify potential markers of AF. The endurance exercise bout resulted in significant alterations to proteins involved in immune modulation (eg, growth/differentiation factor 15), skeletal muscle metabolism (eg, α-actinin-2), cell death (eg, histones), and inflammation (eg, interleukin-6). Subjects with AF differed from those without, displaying modulation of proteins previously known to have associations with incident AF (eg, C-reactive protein, insulin-like growth factor-1, and angiopoietin-2), and also with proteins having no previous association (eg, tapasin-related protein and α2-Heremans-Schmid glycoprotein).
CONCLUSIONS: These findings provide insights into the proteomic response to acute intense exercise, provide mechanistic insights into the pathophysiology behind AF in athletes, and identify targets for future study and validation.
BACKGROUND: Delirium is one of the most common neurological complications after cardiac surgery. The purpose of our study was to assess the relationship between perioperative blood pressure variability (BPV) and postoperative delirium (POD) in the patients undergoing cardiac surgery.
METHODS: Adult patients received cardiac surgery and stayed in Cardiovascular Intensive Care Unit (ICU) for more than 24 h after surgery during the study period between June 2019 and December 2022 were included in this study. Baseline characteristics, perioperative hemodynamic variables and postoperative laboratory results of the cardiac patients were collected and analyzed. Perioperative BPV was quantified by calculating the standard deviation (SD) and average real variability (ARV) of blood pressure. Assessment of delirium was based on the mental status of the patients and CAM-positive. The relationship between perioperative BPV and POD was analyzed by LASSO and logistic regression using R (R package, 4.3.2).
RESULTS: The incidence of POD was 15.0% (324/2164) in the patients receiving cardiac surgery, and the average day for POD occurred at day 3 after surgery. Patients with POD had statistically lower levels of intraoperative mean blood pressure (P = 0.015) and blood pressure ARV (P < 0.001) as well as mean blood pressure at 24 h postoperatively (P = 0.003) when compared to those without. Whereas, ARV for systolic blood pressure (8.64 vs. 7.91 mmHg, P < 0.001), diastolic blood pressure (4.00 vs. 3.77 mmHg, P = 0.014) and mean blood pressure (5.23 vs. 4.94 mmHg, P = 0.001) at 24 h postoperatively was significantly higher in the patients with POD than those without. LASSO regression and further logistic regression revealed that intraoperative blood pressure ARV (OR:0.92, P < 0.001), mean central venous pressure (OR:1.05, P = 0.048) and ARV of systolic blood pressure (OR:1.17, P = 0.002) at 24 h postoperatively were independent risk factors for POD.
CONCLUSIONS: Perioperative ARV, especially postoperative high ARV exposure, was associated with POD in the patients receiving cardiac surgery. Maintaining a relatively stable blood pressure after cardiac surgery might be beneficial to avoid POD in those patients.
Recent studies demonstrated that human papillomavirus (HPV) specific immunoglobulins (IgG) are present and detectable in non-invasively collected first-void urine (FVU) samples. As IgG levels in urine are low, we evaluated the potential of a highly sensitive HPV16-specific assay based on time-resolved fluorescence, DELFIA, and compared it with three immunoassays, GST-L1-MIA, M4ELISA, and M9ELISA. A total of 225 paired serum and FVU samples from two cohorts of healthy female volunteers were analyzed. Strong Spearman rank correlations between HPV16-specific IgG results measured with DELFIA, M4ELISA, GST-L1-MIA, and M9ELISA were found for both sample types (rs > 0.80). Additionally, total human IgG results, determined in all samples using HTRF human IgG kit and BioPlex Pro™ Human Isotyping Assay, were compared. Moderate correlations between total human IgG concentrations in FVU samples were found for the two total IgG assays (rs ≥ 0.42, p < 0.0001), while correlations for serum were non-significant. In conclusion, the HPV16-DELFIA assay is usable for detecting HPV16-specific antibodies in FVU and serum samples. As total human IgG remains an interesting parameter for the normalization of HPV-specific IgG in FVU, the accuracy of both assays needs to be validated further.
Circular RNA (circRNA) has emerged as a pivotal regulatory factor in cancer biology, yet its exact role in cervical cancer remains incompletely understood. In this study, we investigated the functional role of circCUL3 in cervical cancer and explored its potential as a therapeutic target. Functional gain and loss experiments were conducted in Hela and Siha cell lines to elucidate the biological functions of circCUL3 in cervical cancer. The results revealed that circCUL3 overexpression significantly enhanced cell viability, migration, and invasion while suppressing apoptosis, while circCUL3 knockout displayed the opposite effects. Mechanistically, we identified hsa-miR-223-3p as a target of circCUL3, with its expression being negatively regulated by circCUL3. Furthermore, we discovered that circCUL3 could sequester miR-223-3p, leading to the upregulation of ATG7 expression, and this was linked to the regulation of autophagy in cervical cancer cells. In vivo validation using a xenograft mouse model further supported our in vitro findings. Notably, we found that chloroquine (CQ), an autophagy inhibitor, restored miR-223-3p expression and counteracted the oncogenic effect of circCUL3 overexpression. In conclusion, circCUL3 potentially contributes to the malignant progression of cervical cancer by acting as a sponge for miR-223-3p, resulting in the upregulation of ATG7 and the activation of autophagy.
PURPOSE:To obtain an oxytocin antagonist useful for preventing and treating premature birth, dysmenorrhea, delivery inhibition before Caesarean operation, etc., comprising a carbostyril derivative as an active ingredient. CONSTITUTION:An oxytocin antagonist comprises 1-70wt.% compound of the formula (R<1> is H, nitro, lower alkoxy, etc.; R is phenyl, piperidin-4-yl in which nitrogen in the ring is substitutable with alkanoyl, etc.; m is 0-3) such as 1-[1-(4- dimethylaminobenzoyl)-4-piperidinyl]-3,4-dihydrocarbostyril as an active ingredient. The oxytocin antagonist can be pharmaceutically manufactured into a dosage form such as tablet, pill, solution, suspension, emulsion, granule, capsule, injection or suppository. A dose is 0.6-50mg of the compound of the formula based on 1kg weight daily. 10-1,000mg of the compound of the formula is preferably contained in a preparation in an administration unit form. The oxytocin antagonist has inhibitory action on contraction of material smooth muscle, inhibitory action on milk release, inhibitory action on synthesis and release of prostaglandin and vasodilator action.
There is no specific antidote for ondansetron overdose. Patients should be managed with appropriate supportive therapy. Individual intravenous doses as large as 150 mg and total daily intravenous doses as large as 252 mg have been inadvertently administered without significant adverse events. These doses are more than 10 times the recommended daily dose.

In addition to the adverse events listed above, the following events have been described in the setting of ondansetron overdose: “Sudden blindness” (amaurosis) of 2 to 3 minutes’ duration plus severe constipation occurred in 1 patient that was administered 72 mg of ondansetron intravenously as a single dose. Hypotension (and faintness) occurred in a patient that took 48 mg of ondansetron tablets. Following infusion of 32 mg over only a 4-minute period, a vasovagal episode with transient second-degree heart block was observed. In all instances, the events resolved completely.